> top > docs > PubMed:18302761 > annotations

PubMed:18302761 JSONTXT

Annnotations TAB JSON ListView MergeView

PMID_GLOBAL

Id Subject Object Predicate Lexical cue mondo_id
T1 159-176 DiseaseOrPhenotypicFeature denotes Ovarian carcinoma 0005140
T2 459-473 DiseaseOrPhenotypicFeature denotes ovarian cancer 0005140|0008170
T4 607-616 DiseaseOrPhenotypicFeature denotes sensitive 0000605
T5 859-864 DiseaseOrPhenotypicFeature denotes tumor 0005070
T6 1127-1138 DiseaseOrPhenotypicFeature denotes sensitivity 0000605
T7 1592-1597 DiseaseOrPhenotypicFeature denotes tumor 0005070
T8 1844-1858 DiseaseOrPhenotypicFeature denotes ovarian cancer 0005140|0008170
T10 2005-2022 DiseaseOrPhenotypicFeature denotes ovarian carcinoma 0005140

sentences

Id Subject Object Predicate Lexical cue
TextSentencer_T1 0-146 Sentence denotes NCX-4040, a nitric oxide-releasing aspirin, sensitizes drug-resistant human ovarian xenograft tumors to cisplatin by depletion of cellular thiols.
TextSentencer_T2 147-158 Sentence denotes BACKGROUND:
TextSentencer_T3 159-252 Sentence denotes Ovarian carcinoma is the leading cause of mortality among gynecological cancers in the world.
TextSentencer_T4 253-355 Sentence denotes The high mortality rate is associated with lack of early diagnosis and development of drug resistance.
TextSentencer_T5 356-485 Sentence denotes The antitumor efficacy and mechanism of NCX-4040, a nitric oxide-releasing aspirin derivative, against ovarian cancer is studied.
TextSentencer_T6 486-723 Sentence denotes METHODS: NCX-4040, alone or in combination with cisplatin (cis-diamminedichloroplatinum, cDDP), was studied in cisplatin-sensitive (A2780 WT) and cisplatin-resistant (A2780 cDDP) cell lines as well as xenograft tumors grown in nude mice.
TextSentencer_T7 724-820 Sentence denotes Electron paramagnetic resonance (EPR) was used for measurements of nitric oxide and redox state.
TextSentencer_T8 821-919 Sentence denotes Immunoblotting analysis of A2780 cDDP tumor xenografts from mice was used for mechanistic studies.
TextSentencer_T9 920-928 Sentence denotes RESULTS:
TextSentencer_T10 929-1081 Sentence denotes Cells treated with NCX-4040 (25 microM) showed a significant reduction of cell viability (A2780 WT, 34.9 +/- 8.7%; A2780 cDDP, 41.7 +/- 7.6%; p < 0.05).
TextSentencer_T11 1082-1373 Sentence denotes Further, NCX-4040 significantly enhanced the sensitivity of A2780 cDDP cells (cisplatin alone, 80.6 +/- 11.8% versus NCX-4040+cisplatin, 26.4 +/- 7.6%; p < 0.01) and xenograft tumors (cisplatin alone, 74.0 +/- 4.4% versus NCX-4040+cisplatin, 56.4 +/- 7.8%; p < 0.05), to cisplatin treatment.
TextSentencer_T12 1374-1553 Sentence denotes EPR imaging of tissue redox and thiol measurements showed a 5.5-fold reduction (p < 0.01) of glutathione in NCX-4040-treated A2780 cDDP tumors when compared to untreated controls.
TextSentencer_T13 1554-1762 Sentence denotes Immunoblotting analysis of A2780 cDDP tumor xenografts from mice treated with NCX-4040 and cisplatin revealed significant downregulation of pEGFR (Tyr845 and Tyr992) and pSTAT3 (Tyr705 and Ser727) expression.
TextSentencer_T14 1763-1774 Sentence denotes CONCLUSION:
TextSentencer_T15 1775-1919 Sentence denotes The results suggested that NCX-4040 could resensitize drug-resistant ovarian cancer cells to cisplatin possibly by depletion of cellular thiols.
TextSentencer_T16 1920-2060 Sentence denotes Thus NCX-4040 appears to be a potential therapeutic agent for the treatment of human ovarian carcinoma and cisplatin-resistant malignancies.
T1 0-146 Sentence denotes NCX-4040, a nitric oxide-releasing aspirin, sensitizes drug-resistant human ovarian xenograft tumors to cisplatin by depletion of cellular thiols.
T2 147-158 Sentence denotes BACKGROUND:
T3 159-252 Sentence denotes Ovarian carcinoma is the leading cause of mortality among gynecological cancers in the world.
T4 253-355 Sentence denotes The high mortality rate is associated with lack of early diagnosis and development of drug resistance.
T5 356-485 Sentence denotes The antitumor efficacy and mechanism of NCX-4040, a nitric oxide-releasing aspirin derivative, against ovarian cancer is studied.
T6 486-723 Sentence denotes METHODS: NCX-4040, alone or in combination with cisplatin (cis-diamminedichloroplatinum, cDDP), was studied in cisplatin-sensitive (A2780 WT) and cisplatin-resistant (A2780 cDDP) cell lines as well as xenograft tumors grown in nude mice.
T7 724-820 Sentence denotes Electron paramagnetic resonance (EPR) was used for measurements of nitric oxide and redox state.
T8 821-919 Sentence denotes Immunoblotting analysis of A2780 cDDP tumor xenografts from mice was used for mechanistic studies.
T9 920-928 Sentence denotes RESULTS:
T10 929-1081 Sentence denotes Cells treated with NCX-4040 (25 microM) showed a significant reduction of cell viability (A2780 WT, 34.9 +/- 8.7%; A2780 cDDP, 41.7 +/- 7.6%; p < 0.05).
T11 1082-1373 Sentence denotes Further, NCX-4040 significantly enhanced the sensitivity of A2780 cDDP cells (cisplatin alone, 80.6 +/- 11.8% versus NCX-4040+cisplatin, 26.4 +/- 7.6%; p < 0.01) and xenograft tumors (cisplatin alone, 74.0 +/- 4.4% versus NCX-4040+cisplatin, 56.4 +/- 7.8%; p < 0.05), to cisplatin treatment.
T12 1374-1553 Sentence denotes EPR imaging of tissue redox and thiol measurements showed a 5.5-fold reduction (p < 0.01) of glutathione in NCX-4040-treated A2780 cDDP tumors when compared to untreated controls.
T13 1554-1762 Sentence denotes Immunoblotting analysis of A2780 cDDP tumor xenografts from mice treated with NCX-4040 and cisplatin revealed significant downregulation of pEGFR (Tyr845 and Tyr992) and pSTAT3 (Tyr705 and Ser727) expression.
T14 1763-1774 Sentence denotes CONCLUSION:
T15 1775-1919 Sentence denotes The results suggested that NCX-4040 could resensitize drug-resistant ovarian cancer cells to cisplatin possibly by depletion of cellular thiols.
T16 1920-2060 Sentence denotes Thus NCX-4040 appears to be a potential therapeutic agent for the treatment of human ovarian carcinoma and cisplatin-resistant malignancies.

DisGeNET

Id Subject Object Predicate Lexical cue
T0 396-399 gene:3196 denotes NCX
T1 459-473 disease:C0029925 denotes ovarian cancer
T2 396-399 gene:3196 denotes NCX
T3 459-473 disease:C1140680 denotes ovarian cancer
R1 T0 T1 associated_with NCX,ovarian cancer
R2 T2 T3 associated_with NCX,ovarian cancer

DisGeNET5_gene_disease

Id Subject Object Predicate Lexical cue
18302761-11#27#30#gene3196 1802-1805 gene3196 denotes NCX
18302761-11#69#83#diseaseC1140680 1844-1858 diseaseC1140680 denotes ovarian cancer
18302761-12#5#8#gene3196 1925-1928 gene3196 denotes NCX
18302761-12#85#102#diseaseC0029925 2005-2022 diseaseC0029925 denotes ovarian carcinoma
18302761-12#85#102#diseaseC0677886 2005-2022 diseaseC0677886 denotes ovarian carcinoma
27#30#gene319669#83#diseaseC1140680 18302761-11#27#30#gene3196 18302761-11#69#83#diseaseC1140680 associated_with NCX,ovarian cancer
5#8#gene319685#102#diseaseC0029925 18302761-12#5#8#gene3196 18302761-12#85#102#diseaseC0029925 associated_with NCX,ovarian carcinoma
5#8#gene319685#102#diseaseC0677886 18302761-12#5#8#gene3196 18302761-12#85#102#diseaseC0677886 associated_with NCX,ovarian carcinoma

DisGeNet-2017-sample

Id Subject Object Predicate Lexical cue
T513 1802-1805 gene:3196 denotes NCX
T514 1844-1858 disease:C1140680 denotes ovarian cancer
T515 1925-1928 gene:3196 denotes NCX
T516 2005-2022 disease:C0029925 denotes ovarian carcinoma
R1 T513 T514 associated_with NCX,ovarian cancer
R2 T515 T516 associated_with NCX,ovarian carcinoma
R3 T515 T516 associated_with NCX,ovarian carcinoma

UBERON-AE

Id Subject Object Predicate Lexical cue
PD-UBERON-AE-B_T1 1389-1395 http://purl.obolibrary.org/obo/UBERON_0000479 denotes tissue

performance-test

Id Subject Object Predicate Lexical cue
PD-UBERON-AE-B_T1 1389-1395 http://purl.obolibrary.org/obo/UBERON_0000479 denotes tissue